Targeting the underlying
genetic cause of disease for

UNDERSERVED
PATIENTS.

PURPOSE

We are an integrated genetic medicines company developing targeted, disease-modifying medicines for patients with life-limiting respiratory diseases. Our treatments address the underlying genetic cause in underserved populations and have the potential to tremendously impact the quality and length of patients’ lives.

NON-VIRAL DELIVERY TECHNOLOGY

We have created a broad and customizable platform of non-viral lipid nanoparticles (LNPs), enabling us to precisely deliver our medicines safely and effectively.

With our SORT LNP delivery platform, we can hone in on previously inaccessible targets by delivering the payload precisely to a specific organ. Our proprietary delivery platforms can be customized to treat different respiratory diseases and targeted organs. Our ability to carry different types of cargo (mRNA, tRNA, CRISPR) with multiple delivery systems allows us to advance several drug candidates simultaneously. Ultimately, we match the best delivery approach to the specific problem, providing incredible flexibility in how we can potentially treat patients.

PROGRAMS

By harnessing our deep experience with well-defined drug development and regulatory pathways, we will rapidly advance our lead programs for cystic fibrosis (CF) caused by nonsense mutations and primary ciliary dyskinesia (PCD) – ultimately having a significant effect where there is a clear, unmet, and high-hurdle need.

CF and PCD are complex diseases to treat, as targeted delivery and restoration of function are big hurdles to overcome. Considering these patients are coping with a compromised quality of life and facing a significantly shortened lifespan, we must meet this need.

Our programs in CF and PCD are currently in preclinical stages of development. Our CF program is supported by a grant from the Cystic Fibrosis Foundation, whose support has allowed us to better understand the pathogenesis of CF and develop a novel therapeutic approach for correcting nonsense mutations for this severe disease.

INDICATION

DELIVERY

DISCOVERY

PRECLINICAL

PHASE 1

PHASE 2

CF

Inhaled or IV

PRECLINICAL

Cystic fibrosis (CF) is a progressive, genetic disease that causes persistent lung infections and limits the ability to breathe over time. In people with CF, mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene cause the CFTR protein to become dysfunctional, triggering the mucus in various organs to become thick and sticky. In the lungs, the mucus clogs the airways and traps germs, leading to infections, inflammation, respiratory failure and other complications. Our treatment for CF focuses specifically on the 10%-13% of CF patients who have nonsense mutations that can’t fully benefit from current small molecule therapies.

PCD

Inhaled

PRECLINICAL

Primary ciliary dyskinesia (PCD) is a disease characterized by deficient mucociliary clearance (MCC), chronic respiratory tract infections and premature death. This rare disease is caused by mutations in more than 40 different genes that result in dysfunctional cilia and loss of MCC. PCD is a life-limiting disease with no disease-modifying treatments available to patients.

MANAGEMENT

SHEHNAAZ SULIMAN, M.D., MBA, M.Phil.

Chief Executive Officer

DAVID J. LOCKHART, Ph.D.

President & Chief Scientific Officer

ANGÈLE MAKI, Ph.D.

Senior Vice President, Business Development

BRANDON A. WUSTMAN, Ph.D.

Senior Vice President of R&D

NICK P. FRANCE, M.D.

Senior Vice President, Clinical Development

VLADIMIR G. KHARITONOV, Ph.D.

Senior Vice President, CMC

ARUNAN KALIYAPERUMAL, Ph.D.

Vice President, Preclinical Research

MICHAEL TORRES, Ph.D.

Vice President, R&D, Texas Site Head

BOARD OF DIRECTORS

RANA AL-HALLAQ, Ph.D.

Pfizer Ventures

ED HURWITZ, J.D., M.B.A.

MPM Capital

HELEN S. KIM, M.B.A.

Vida Ventures

SHEHNAAZ SULIMAN, M.D., MBA, M.Phil.

ReCode Therapeutics

DAVID J. LOCKHART, Ph.D.

ReCode Therapeutics

OLEG NODELMAN

EcoR1 Capital

RA SESSION II

Taysha Gene Therapies

PETER THOMPSON, M.D.

OrbiMed

SCIENTIFIC ADVISORS

ARTHUR E. JOHNSON, Ph.D.

Advisor

DANIEL J. SIEGWART, Ph.D.

Advisor, Collaborator

PHILIP THOMAS, Ph.D.

Advisor

INVESTORS

News

Presentations

Publications

CAREERS

At ReCode, we bring a unique blend of rigor, creativity, and curiosity to our high-hurdle mission: harnessing our multi-platform approach to develop disease-modifying medicines. Our team is uniquely positioned to tackle this challenge, given our extensive experience in RNA delivery technologies, protein structure, tRNA biology, mRNA manufacturing, gene editing, and drug development.

Would you like to be a part of the ReCode team? Browse our open positions below.